第3代双源CT低剂量前列腺CT灌注的可行性

Feasibility Study of Low-dose Prostate CT Perfusion on Third-generation Dual-source CT

目的探讨在第3代双源CT上行低剂量前列腺CT灌注(p CTP)的可行性。方法 9例前列腺特异性抗原升高的患者在接受前列腺活检穿刺前行p CTP。测量病灶与正常前列腺组织的血流量(BF)、血容量(BV)、平均通过时间(MTT)、表面通透性(PS)和达峰时间(TTP)。计算有效剂量(ED)。结果 9例患者中,6例为前列腺癌,3例为前列腺增生伴慢性炎性改变。9例p CTP检查的平均ED为(3.5±0.3)m Sv。前列腺癌的BF(t=4.64,P<0.001)、BV(t=3.27,P<0.001)和PS(t=3.58,P=0.004)均明显高于正常前列腺组织,TTP(t=-1.26,P<0.001)明显低于正常前列腺组织;前列腺增生伴慢性炎性改变的BF(t=3.96,P=0.001)和PS(t=2.91,P=0.021)也明显高于正常前列腺组织,TTP(t=-1.19,P<0.001)明显低于正常前列腺组织;前列腺癌的TTP明显低于前列腺增生伴慢性炎性改变(t=-2.56,P=0.049)。结论第3代双源CT可实现低剂量p CTP,前列腺癌、前列腺增生伴慢性炎性改变和正常前列腺组织的BF、PS和TTP存在显著差异。

Objective To investigate the feasibility of using low-dose prostate CT perfusion（ p CTP）on a third-generation dual-source CT. Methods Nine patients with elevated prostate-specific antigen underwent p CTP before having prostate biopsy. We measured the blood flow（ BF）, blood volume（ BV）, mean transit time（MTT）,permeability surface（PS）,and time to peak（TTP） of both lesions and normal prostate tissue. The effective dose（ ED） was calculated. Results Of the 9 cases,6 were prostate cancers and 3 were prostate hyperplasia with chronic inflammation. The average ED of the 9 p CTPs was（ 3. 5 ± 0. 3） m Sv. The BF（ t = 4. 64,P〈0. 001）, BV（ t = 3. 27, P〈0. 001）, and PS（ t = 3. 58, P = 0. 004） of prostate cancer were significantly higher than those of normal prostate tissue and TTP（ t =- 1. 26, P〈0. 001） of prostate cancer was significantly lower than that of normal prostate tissue. BF（ t = 3. 96, P = 0. 001） and PS（ t = 2. 91, P = 0. 021） of prostate hyperplasia with chronic inflammation were also significantly higher and TTP（ t =- 1. 19, P〈0. 001） was sig-nificantly lower than those of normal prostate tissue. TTP of prostate cancer was significantly lower than that of prostate hyperplasia with chronic inflammation（ t =- 2. 56, P = 0. 049）. Conclusions Low-dose p CTP is feasible on third-generation dual-source CT. The BF, PS, and TTP differ among prostate cancer, prostate hyperplasia with chronic inflammation, and normal prostate tissue.